邁博藥業-B(02181.HK)與科興生物製藥訂立CMAB008(英夫利西單抗)於中國內地獨家推廣服務協議
格隆匯3月31日丨邁博藥業-B(02181.HK)公吿，於2022年3月30日，公司間接全資附屬公司泰州邁博太科藥業有限公司("泰州藥業")與科興生物製藥股份有限公司("科興生物製藥")(上海證券交易所科創板上市公司(股份代號：688136))訂立獨家推廣服務協議，據此，泰州藥業已向科興生物製藥授出CMAB008類停於中國內地(不包括香港、澳門及台灣地區)("推廣服務區域")的獨家推廣許可，泰州藥業將就此獨家推廣許可收取合作里程碑款及商業里程碑款項，未來亦有望獲得持續銷售產生的可觀收入。
雙方在該協議中約定了目標銷售量，如藥品銷售量未達目標，則泰州藥業有權解除合同或者由科興生物製藥根據該協議約定補償後繼續履行合同。而泰州藥業將繼續擁有CMAB008類停於推廣服務區域內除推廣權外的所有權利及權益。
公司產品管線覆蓋免疫、過敏性、腫瘤、消化等科室的藥物，公司銷售策略上將更加聚焦優勢科室相應藥物的銷售，積極與擁有豐富經驗且已長期積累資源的企業合作以快速實現市場銷售資源導入和市場份額的高速提升，發揮規模效應和合作放大效應；訂立該協議將有利於提升CMAB008類停的品牌影響力，為本公司產品銷售額的高速增長提供指數級倍增動力。
CMAB008類停®(英夫利西單抗)：於2021年七月獲中華人民共和國國家藥品監督管理局批准上市(國藥準字S20210025)，可用於治療1)成人潰瘍性結腸炎；2)強直性脊柱炎；3)類風濕關節炎；4)成人及6歲以上兒童克羅恩病；5)瘻管性克羅恩病；及6)銀屑病。泰州藥業位於江蘇泰州中國醫藥城抗體藥物生產基地亦已順利通過江蘇省藥品監督管理局對於CMAB008類停的良好生產規範(GMP)符合性檢查。
根據中國的基本醫療保險計劃("醫保")規定，CMAB008類停已獲自動納入醫保，並已獲得國家醫療保障局頒發的醫保註冊碼。CMAB008類停獲批用於六個適應症的治療，此等適應症中國患病人數超過1,000萬人且持續增長，具有巨大長期未滿足的市場需求。
根據米內網統計，2021年上半年進口英夫利西單抗在中國公立醫院的半年銷售額為人民幣5.5億元，同比增長105%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
